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Abstract
In this opinion, the GMO Panel assessed the four-event stack maize 1507 9 59122 9 MON810 9
NK603 and its ten subcombinations, independently of their origin. The GMO Panel previously assessed
the four single events combined in this four-event stack maize and ﬁve of their combinations and did
not identify safety concerns. No new data on the single events or their previously assessed
combinations leading to modiﬁcation of the original conclusions were identiﬁed. Based on the molecular,
agronomic, phenotypic and compositional characteristics, the combination of the single maize events
and of the newly expressed proteins in the four-event stack maize did not give rise to food and feed
safety or nutritional issues. The GMO Panel concludes that the four-event stack maize is as safe and as
nutritious as its non-GM comparator. In the case of accidental release of viable grains of maize
1507 9 59122 9 MON810 9 NK603 into the environment, this would not raise environmental safety
concerns. For four of the subcombinations not previously assessed, protein expression data were
provided and did not indicate an interaction affecting the levels of the newly expressed proteins in these
subcombinations. The ﬁve subcombinations not previously assessed are expected to be as safe as the
single maize events, the previously assessed subcombinations and the four-event stack maize. The GMO
Panel considers that post-market monitoring of maize 1507 9 59122 9MON810 9 NK603 and its
subcombinations is not necessary. The post-market environmental monitoring plan and reporting
intervals are in line with the intended uses of maize 1507 9 59122 9 MON810 9NK603 and its
subcombinations.
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Summary
Following the submission of application EFSA-GMO-NL-2011-92 under Regulation (EC) No 1829/2003
from Pioneer, the Panel on Genetically Modiﬁed Organisms of the European Food Safety Authority
(referred to hereafter as the GMO Panel) was asked to deliver a Scientiﬁc Opinion on the safety
of genetically modiﬁed glufosinate- and glyphosate-tolerant and insect-resistant maize
1507 9 59122 9 MON810 9 NK603 and its subcombinations independently of their origin, according to
Regulation (EU) No 503/2013 (referred to hereafter as ‘subcombinations’). The scope of application
EFSA-GMO-NL-2011-92 is for the placing on the market of maize 1507 9 59122 9 MON810 9 NK603
and all its subcombinations, independently of their origin, for food and feed uses, import and processing.
The term ‘subcombination’ refers to any combination of up to three of the events present in the four-
event stack maize. The safety of subcombinations occurring as segregating progeny in the harvested
grains of maize 1507 9 59122 9 MON810 9 NK603 is evaluated in the context of the assessment of
the four-event stack maize in Section 3.3 of the present GMO Panel Scientiﬁc Opinion. The safety of
subcombinations that have either been, or could be produced by conventional crossing through targeted
breeding approaches, and which can be bred, produced and marketed independently of the four-event
stack, are risk assessed in the Section 3.4 of the present GMO Panel Scientiﬁc Opinion.
In delivering its Scientiﬁc Opinion, the GMO Panel considered the data available on the single
events, the four-event stack maize, a three-event and four two-event stack subcombinations, the
scientiﬁc comments submitted by the Member States, and relevant scientiﬁc literature. The four-event
stack maize was produced by conventional crossing to combine four maize events: 1507 expressing
the Cry1F protein which confers protection against speciﬁc lepidopteran pests and phosphinothricin
acetyl transferase (PAT) protein for tolerance to glufosinate-ammonium-containing herbicides; 59122
expressing the Cry34Ab1 and Cry35Ab1 proteins to confer protection against coleopteran pests
belonging to the genus Diabrotica and the PAT protein for tolerance to glufosinate-ammonium-
containing herbicides; MON810 expressing the Cry1Ab protein to confer protection against speciﬁc
lepidopteran pests; and NK603 expressing the 5-enolpyruvylshikimate-3-phosphate synthase (CP4
EPSPS) protein and its variant CP4 EPSPS L214P for tolerance to glyphosate- containing herbicides.
The GMO Panel evaluated the four-event stack maize and its subcombinations with reference to the
scope and appropriate principles described in its guidelines for the risk assessment of GM plants and
derived food and feed, the environmental risk assessment of GM plants and the post-market
environmental monitoring of GM plants. The GMO Panel Guidance Documents establish the principle that
where all single events have been assessed, the risk assessment of stacked events should focus mainly
on issues related to (a) stability of the inserts, (b) expression of the introduced genes and their products
and (c) potential synergistic or antagonistic effects resulting from the combination of the events.
For application EFSA-GMO-NL-2011-92, previous assessments of the four single maize events
(1507, 59122, MON810 and NK603), the three-event stack maize 59122 9 1507 9 NK603 and four
two-event stack maize (1507 9 59122, 1507 9 NK603, 59122 9 NK603 and NK603 9 MON810)
provided a basis to evaluate the four-event stack maize and all its subcombinations. Maize 1507,
59122, MON810, NK603, 1507 9 59122, 1507 9 NK603, 59122 9 NK603 and NK603 9 MON810,
and 59122 9 1507 9 NK603 were previously assessed by the GMO Panel and no concerns on their
safety were identiﬁed. No safety issue concerning the four single maize events was identiﬁed by the
updated bioinformatic analyses, nor reported by the applicant since the publication of the previous
GMO Panel Scientiﬁc Opinions. Therefore, the GMO Panel considers that its previous conclusions on
the safety of the single maize events remain valid.
For the four-event stack maize, the risk assessment included the molecular characterisation of the
inserted DNA and analysis of protein expression. An evaluation of the comparative analyses of
agronomic/phenotypic and compositional characteristics was undertaken, and the safety of the newly
expressed proteins and the whole food/feed were evaluated with respect to potential toxicity,
allergenicity and nutritional characteristics. An evaluation of environmental impacts and post-market
environmental monitoring plans was also undertaken.
The molecular data establish that the events stacked in maize 1507 9 59122 9 MON810 9 NK603
have retained their integrity. Protein expression analyses showed that the levels of the newly
expressed proteins are similar in the four-event stack maize and in the single events except for the
expected difference in PAT protein levels resulting from the combination of 1507 and 59122 events,
both producing PAT protein in the four-event stack. No indications of interactions that may affect the
integrity of the events and the levels of the newly expressed proteins in this four-event stack maize
were identiﬁed.
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No relevant differences between maize 1507 9 59122 9 MON810 9 NK603 and the non-GM
comparator requiring further assessment regarding food and feed safety and environmental impact
were identiﬁed in grain and forage composition and in the tested agronomic and phenotypic
characteristics.
Based on the molecular, agronomic, phenotypic or compositional characteristics, the combination of
maize events 1507, 59122, MON810, and NK603 in the four-event stack maize did not give rise to
issues regarding food and feed safety and nutrition. The combination of the newly expressed proteins
in the four-event stack maize did not raise concerns for human and animal health.
Considering the events combined, their potential interactions, the outcome of the comparative
analysis, and the routes and levels of exposure, the GMO Panel concludes that maize
1507 9 59122 9 MON810 9 NK603 would not raise safety concerns in the case of accidental release
of viable GM maize grains into the environment.
The GMO Panel concludes that the four-event stack maize is as safe and as nutritious as the non-
GM comparator in the context of the scope of this application.
Maize 1507 9 59122 9 MON810 9 NK603 has 10 possible subcombinations of which ﬁve have
been previously assessed. Since no safety concerns were identiﬁed for the previously assessed two-
event stack maize 1507 9 59122, 1507 9 NK603, 59122 9 NK603 and NK603 9 MON810, and the
three-event stack maize 59122 9 1507 9 NK603, and no new data leading to the modiﬁcation of the
original conclusions on safety were identiﬁed, the GMO Panel considers that its previous conclusions on
these maize subcombinations remain valid. For four of the subcombinations not previously assessed,
protein expression data were provided and did not indicate an interaction affecting the levels of the
newly expressed proteins in these subcombinations. The GMO Panel assessed the possibility of
interactions between the events in these ﬁve subcombinations and concluded that these combinations
would not raise safety concerns. The ﬁve subcombinations not previously assessed are expected to be
as safe as the single maize events, the previously assessed maize 1507 9 59122, 1507 9 NK603,
59122 9 NK603 and NK603 9 MON810 and the three-event stack maize 59122 9 1507 9 NK603, as
well as the four-event stack maize 1507 9 59122 9 MON810 9 NK603.
Given the absence of safety concerns for food and feed derived from maize
1507 9 59122 9 MON 810 9 NK603 and its subcombinations, the GMO Panel considers that post-
market monitoring of these products is not necessary. The post-market environmental monitoring plan
and reporting intervals are in line with the intended uses of the four-event stack maize and its
subcombinations.
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1. Introduction
1.1. Background
On 3 February 2011, the European Food Safety Authority (EFSA) received from the Competent
Authority of the Netherlands application EFSA-GMO-NL-2011-92, for authorisation of genetically
modiﬁed (GM) maize 1507 9 59122 9 MON810 9 NK603. This application was submitted by Pioneer
Overseas Corporation (referred to hereafter as the applicant), within the framework of Regulation (EC)
No 1829/20031, for food and feed uses, import and processing2, in accordance with Articles 3(1) and
15(1) of Regulation (EC) 1829/2003. The risk assessment of application EFSA-GMO-NL-2011-92
presented here is for the placing on the market of four-event stack maize and all its subcombinations
independently of their origin, for food and feed uses (see Table 1).
After receiving the application EFSA-GMO-NL-2011-92 and in accordance with Articles 5(2)(b) and
17(2)(b) of Regulation (EC) No 1829/2003, EFSA informed Member States and the European
Commission, and made the summary of the application available to the public on the EFSA website.
EFSA initiated a formal review of the application to check compliance with the requirements laid down
in Articles 5(3) and 17(3) of Regulation (EC) No 1829/2003. EFSA requested additional information
under completeness check on 30 March 2011, 9 June 2011 and 22 November 2011, respectively; the
applicant provided the information on 17 May 2011, 25 October 2011 and 9 January 2012 respectively.
On 30 January 2012, EFSA declared the application valid in accordance with Articles 6(1) and 18(1) of
Regulation (EC) No 1829/2003.
EFSA made the valid application available to Member States and the European Commission, and
consulted nominated risk assessment bodies of Member States, including national Competent Authorities
within the meaning of Directive 2001/18/EC3 following the requirements of Articles 6(4) and 18(4) of
Regulation (EC) No 1829/2003, to request their scientiﬁc opinion. Member States had 3 months after
the date of receipt of the valid application (i.e., until 30 April 2012) to make their opinion known.
The EFSA GMO Panel carried out an evaluation of the scientiﬁc risk assessment of the four-event
stack maize and its subcombinations, independently of their origin (Table 1) (referred to as
‘subcombinations’, according to the Regulation (EU) No 503/2013).
EFSA and the GMO Panel requested additional information on 1 March 2012 (EURL-GMFF), 13 April
2012, 11 July 2012, 24 September 2012, 9 January 2013, 7 January 2014, 14 March 2014, 13 June
2014, 27 October 2014, 15 December 2014, 11 December 2015, 1 June 2016, 3 August 2016, 17
October 2016, 8 March 2017 and 18 May 2017, respectively. The applicant provided the requested
information on 31 May 2012, 2 October 2012, 10 December 2012, 11 December 2012 (EURL-GMFF),
20 February 2013, 6 May 2014, 6 August 2014, 18 August 2014, 5 February 2015, 19 November 2015,
25 November 2015, 23 May 2016, 7 July 2016, 12 October 2016, 23 January 2017, 9 June 2017 and
21 August 2017. The applicant also submitted spontaneous information on 9 June 2017.
In the frame of contract OC/EFSA/UNIT/GMO/2013/01, the contractor performed preparatory work
and delivered reports on the methods applied by the applicant in performing bioinformatic analyses.
In giving its Scientiﬁc Opinion to the European Commission, Member States and the applicant, and
in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003, EFSA has endeavoured to
respect a time limit of 6 months from the acknowledgement of the valid application. As additional
information was requested by the EFSA GMO Panel, the time limit of 6 months was extended
accordingly, in line with Articles 6(1), 6(2), 18(1) and 18(2) of Regulation (EC) No 1829/2003.
According to Regulation (EC) No 1829/2003, this scientiﬁc opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation, and thus will be part of the EFSA overall
opinion in accordance with Articles 6(5) and 18(5).
1.2. Terms of Reference as provided by the requestor
The EFSA GMO Panel was requested to carry out a scientiﬁc risk assessment of ‘maize
1507 9 59122 9 MON810 9 NK603 and ten sub-combinations of the single events, independently of
their origin’ (Table 1) for food and feed uses, import and processing, in accordance with Articles 6(6)
and 18(6) of Regulation (EC) No 1829/2003.
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed.
2 In accordance with Part C of Directive 2001/18/EC.
3 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modiﬁed organisms and repealing Council Directive 90/220/EEC.
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Where applicable, any conditions or restrictions which should be imposed on the placing on the
market and/or speciﬁc conditions or restrictions for use and handling, including post-market monitoring
requirements based on the outcome of the risk assessment and, in the case of GMOs or food/feed
containing or consisting of GMOs, conditions for the protection of particular ecosystems/environment
and/or geographical areas should be indicated in accordance with Articles 6(5)(e) and 18(5)(e) of
Regulation (EC) No 1829/2003.
The EFSA GMO Panel was not requested to give an opinion on information required under Annex II
to the Cartagena Protocol. Furthermore, the EFSA GMO Panel did not consider proposals for labelling
and methods of detection (including sampling and the identiﬁcation of the speciﬁc transformation
event in the food/feed and/or food/feed produced from it), which are matters related to risk
management.
2. Data and methodologies
2.1. Data
In delivering its scientiﬁc opinion, the GMO Panel took into account application EFSA-GMO-NL-2011-92,
additional information provided by the applicant, scientiﬁc comments submitted by the Member States
and relevant scientiﬁc publications.
2.2. Methodologies
The GMO Panel carried out a scientiﬁc risk assessment of maize 1507 9 59122 9
MON810 9 NK603 and its ten subcombinations,4 independently of their origin (Table 1), for food and
feed uses, in accordance with Articles 6(6) and 18(6) of Regulation (EC) No 1829/2003. The GMO
Panel took into account the appropriate principles described in its guidelines for the risk assessment of
GM plants and derived food and feed (EFSA, 2006a, 2007a; EFSA GMO Panel, 2011a), the
environmental risk assessment (ERA) of GM plants (EFSA GMO Panel, 2010), and the post-market
environmental monitoring (PMEM) of GM plants (EFSA GMO Panel, 2011b).
The comments raised by Member States are addressed in Annex G of EFSA’s overall opinion and
were taken into consideration during the scientiﬁc risk assessment.
3. Assessment
3.1. Introduction
Application EFSA-GMO-NL-2011-92 covers the four-event stack maize 1507 9 59122 9
MON810 9 NK603 and its 10 subcombinations independently of their origin (Table 1). The scope of
this application is for food and feed uses, and excludes cultivation within the European Union (EU).
The term ‘subcombination’ refers to any combination of up to three of the events present in the
four-event stack maize.
The safety of subcombinations occurring as segregating progeny in harvested grains of maize
1507 9 59122 9 MON810 9 NK603 is evaluated in the context of the assessment of the four-event
stack maize in Section 3.3 of the present GMO Panel Scientiﬁc Opinion.
‘Subcombination’ also covers combinations of three or two of the four events 1507, 59122, MON810
and NK603 that have either been or could be produced by conventional crossing through targeted
breeding approaches (EFSA GMO Panel, 2011a). These maize stacks, that can be bred, produced and
marketed independently of the four-event stack maize, are assessed in the Section 3.4 of this GMO
Panel Scientiﬁc Opinion.
The four-event stack maize was produced by conventional crossing to combine four maize events:
1507 (expressing the Cry1F and phosphinothricin acetyl transferase (PAT) proteins), 59122 (expressing
the Cry34Ab1, Cry35Ab1 and PAT proteins), MON810 (expressing Cry1Ab), and NK603 (expressing the
5-enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS) and its variant CP4 EPSPS L214P protein).
4 For the risk assessment of subcombinations, the GMO Panel used the strategy indicated in its 115th GMO Panel meeting (Annex
1 of the minutes: http://www.efsa.europa.eu/sites/default/files/event/170517-m.pdf).
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Herbicidal tolerance traits are achieved by the expression of CP4 EPSPS proteins from
Agrobacterium sp. strain CP4, and PAT protein from Streptomyces viridochromogenes. Insecticidal
resistance traits are achieved by the expression of the Cry1F, Cry34Ab1, Cry35Ab1 and Cry1Ab proteins
from Bacillus thuringiensis, which confer protection against speciﬁc lepidopteran (e.g. Ostrinia nubilalis
(European corn borer) and species belonging to the genus Sesamia) and coleopteran pests (Diabrotica
spp. (corn rootworm larvae)).
All four single maize events, four two-event stacks (1507 9 59122, 1507 9 NK603,
59122 9 NK603 and NK603 9 MON810) and one three-event stack (59122 9 1507 9 NK603) have
been previously assessed (see Table 2), and no safety concerns were identiﬁed.
EFSA guidance establishes the principle that ‘For GM plants containing a combination of
transformation events (stacked events) the primary concern for risk assessment is to establish that the
combination of events is stable and that no interactions between the stacked events, that may raise
safety concerns compared to the single events, occur. The risk assessment of GM plants containing
stacked events focuses on issues related to: (a) stability of the inserts, (b) expression of the
introduced genes and their products and (c) potential synergistic or antagonistic effects resulting from
the combination of the events’ (EFSA, 2007a, EFSA GMO Panel, 2011a).
Table 2: Single maize events and subcombinations of maize 1507 9 59122 9 MON810 9 NK603
previously assessed by the GMO Panel
Events Application or mandate EFSA Scientiﬁc Opinions
1507 C/NL/00/10
C/ES/01/01
EFSA-GMO-NL-2004-02
EFSA-GMO-RX-1507
2004a
2005a
2005b
2009a
59122 EFSA-GMO-NL-2005-12
EFSA-GMO-NL-2005-23
2007b
2013
MON810 EFSA-GMO-RX-MON810 2009b
NK603 CE/ES/00/01
Article 4 of the Novel Food Regulation (EC) No 258/97
EFSA-GMO-NL-2005-22
EFSA-GMO-RX-NK603
2007c
2004b
2009c
2009c
1507 9 59122 EFSA-GMO-NL-2005-15 2009d
1507 9 NK603 EFSA-GMO-UK-2004-05 2006b
59122 9 NK603 EFSA-GMO-UK-2005-20 2008
NK603 9 MON810 C/GB/02/M3/3
EFSA-GMO-UK-2004-01
2005c
2005d
59122 9 1507 9 NK603 EFSA-GMO-UK-2005-21 2009e
Table 1: Stacked maize events covered by the scope of application EFSA-GMO-NL-2011-92.
Degree of
Stacking
Events Unique Identiﬁers
Four-event
stack maize
1507 9 59122 9 MON810 9 NK603 DAS-Ø15Ø7-1 9 DAS-59122-7 9 MON-ØØ81Ø-6 9
MON-ØØ6Ø3-6
Three-event
stack maize
1507 9 59122 9 MON810 DAS-Ø15Ø7-1 9 DAS-59122-7 9 MON-ØØ81Ø-6
1507 9 MON810 9 NK603 DAS-Ø15Ø7-1 9 MON-ØØ81Ø-6 9 MON-ØØ6Ø3-6
59122 9 1507 9 NK603 DAS-59122-7 9 DAS-Ø15Ø7-1 9 MON-ØØ6Ø3-6
59122 9 MON810 9 NK603 DAS-59122-7 9 MON-ØØ81Ø-6 9 MON-ØØ6Ø3-6
Two-event
stack maize
1507 9 59122 DAS-Ø15Ø7-1 9 DAS-59122-7
1507 MON810 DAS-Ø15Ø7-1 9 MON-ØØ81Ø-6
1507 9 NK603 DAS-Ø15Ø7-1 9 MON-ØØ6Ø3-6
59122 9 MON810 DAS-59122-7 9 MON-ØØ81Ø-6
59122 9 NK603 DAS-59122-7 9 MON-ØØ6Ø3-6
NK603 9 MON810 MON-ØØ6Ø3-6 9 MON-ØØ81Ø-6
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3.2. Updated information on the events
Since the publication of the scientiﬁc opinions on the single maize events (see Table 2), no safety
issue concerning any of the four single events has been reported by the applicant.
The applicant clariﬁed that the maize 59122 sequence reported in this application corresponds to
the sequence submitted in the original application EFSA-GMO-NL-2005-12 of the single event (EFSA,
2007b), but corrected for sequencing errors affecting three single nucleotides.5 In addition, the
applicant clariﬁed that the maize 1507 sequence reported in this application is identical to the
corrected maize 1507 sequence.6 Analysis of the corrected sequencing data and the bioinformatic
analyses performed on these sequences did not give rise to safety issues (EFSA GMO Panel, 2016 and
2017 respectively).
Updated bioinformatic analyses of the ﬂanking regions of events 1507, 59122, MON810 and NK603
conﬁrmed that no known endogenous genes were disrupted by any of the inserts.7 Updated
bioinformatic analyses of the amino acid sequence of the newly expressed Cry1F, PAT, Cry34Ab1,
Cry35Ab1, Cry1Ab and CP4 EPSPS proteins conﬁrmed previous analyses indicating no signiﬁcant
similarities to toxins or allergens; updated bioinformatics analyses of the newly created open reading
frames (ORFs) within the inserts, or spanning the junctions between the inserts and the ﬂanking
regions, conﬁrmed previous analyses indicating that the expression of an ORF showing signiﬁcant
similarities to toxins or allergens is highly unlikely.7
Based on the above information, the GMO Panel considers that its previous conclusions on the
safety of the single maize events remain valid.
3.3. Risk assessment of maize 1507 3 59122 3 MON810 3 NK603
3.3.1. Molecular characterisation
Possible interactions that would affect the integrity of the events, protein expression level, or the
biological function conferred by the individual inserts are considered below.
3.3.1.1. Genetics elements and their biological function8
Maize events 1507, 59122, MON810 and NK603 were combined by conventional crossing to
produce the four event-stack 1507 9 59122 9 MON810 9 NK603. The structure of the inserts
introduced into maize 1507, 59122, MON810 and NK603 is described in detail in the respective EFSA
scientiﬁc opinions (Table 2) and no new genetic modiﬁcations were involved. Genetic elements in the
expression cassettes of the single events are summarised in Table 3.
Intended effects of the inserts in maize 1507 9 59122 9 MON810 9 NK603 are summarised in
Table 4.
Based on the known biological function of the newly expressed proteins (Table 4), the only
foreseeable interactions at the biological level are between the Cry proteins in susceptible insects (see
Section 3.3.4.4).
Table 3: Genetic elements in the expression cassettes of the events stacked in maize
1507 9 59122 9 MON810 9 NK603
Event Promoter 5’ UTR
Transit
peptide
Coding region Terminator
1507(a) ubiZM1
(Zea mays)
– – cry1F
(Bacillus thuringiensis)
ORF25PolyA
(Agrobacterium
tumefaciens)
35S
(CaMV)
– – pat
(Streptomyces
viridochromogenes)
35S
(CaMV)
5 Additional information: 12/10/2016 and 23/1/2017.
6 Additional information: 21/8/2017.
7 Additional information: 19/11/2016 and 9/6/2017.
8 Part I—Section C.
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Event Promoter 5’ UTR
Transit
peptide
Coding region Terminator
59122 ubiZM1
(Z. mays)
– – cry34Ab1
(B. thuringiensis)
pinII
(Solanum
tuberosum)
wheat peroxidase
(Triticum aestivum)
– – cry35Ab1
(B. thuringiensis)
pinII
(S. tuberosum)
35S
(CaMV)
– – pat
(S. viridochromogenes)
35S
(CaMV)
MON810 35S
(CaMV)
(partial)
I-Hsp70
(Z. mays)
– cry1Ab
(B. thuringiensis)
(partial)
(deleted during
integration)
NK603(b) ract1
(Oryza sativa)
ract1
(O. sativa)
ctp2
(Arabidopsis
thaliana)
CP4 epsps
(Agrobacterium sp)
nos
(A. tumefaciens)
35S
(CaMV)
I-Hsp70
(Z. mays)
ctp2
(A. thaliana)
CP4 epsps l214p
(Agrobacterium sp)
nos
(A. tumefaciens)
CaMV: cauliﬂower mosaic virus; UTR: untranslated region; CTP: chloroplast transit peptide.
(–): When no element was speciﬁcally introduced to optimise expression.
(a): Maize 1507 also contains partial fragments of the cry1F and pat genes at a single locus in the nuclear genome.
(b): Maize NK603 also includes at the 3’ end an additional 217 bp DNA fragment of the rice actin promoter, lacking sequences
needed for promoter activity.
Table 4: Characteristics and intended effects of the events stacked in maize
1507 9 59122 9 MON810 9 NK603
Event Protein
Donor organism and biological
function
Intended effects in GM plant
1507 Cry1F Based on a gene from B. thuringiensis
subsp. aizawai. B. thuringiensis is an insect
pathogen; its insecticidal activity is
attributed to the expression of crystal
protein (cry) genes (Schnepf et al., 1998)
Event 1507 expresses a synthetic version of
the truncated Cry1F protein. Cry1F is a
protein toxic to certain lepidopteran larvae
feeding on maize
PAT Based on a gene from
S. viridochromogenes strain T€u494.
Phosphinothricin-acetyl-transferase (PAT)
enzyme confers resistance to the antibiotic
bialaphos (Wohlleben et al., 1988)
Event 1507 expresses the PAT protein,
which acetylates L-glufosinate-ammonium
and thereby confers tolerance to glufosinate
ammonium-based herbicides
59122 Cry34Ab1 Based on a gene from B. thuringiensis
strain PS149B1. B. thuringiensis is an insect
pathogen; its insecticidal activity is
attributed to the expression of crystal
protein (cry) genes (Schnepf et al., 1998;
Ellis et al., 2002)
Event 59122 expresses a cry34Ab1 gene
which was modiﬁed to enhance expression
in plants. The amino acid sequence was not
modiﬁed. Cry34Ab1 is a protein toxic to
certain coleopteran larvae feeding on maize
Cry35Ab1 Based on a gene from B. thuringiensis
strain PS149B1. B. thuringiensis is an insect
pathogen; its insecticidal activity is
attributed to the expression of crystal
protein (cry) genes (Schnepf et al., 1998;
Ellis et al., 2002)
Event 59122 expresses a cry35Ab1 gene
which was modiﬁed to enhance expression
in plants. The amino acid sequence was not
modiﬁed. Cry35Ab1 is a protein toxic to
certain coleopteran larvae feeding on maize
PAT Based on a gene from
S. viridochromogenes.
Phosphinothricin-acetyl-transferase (PAT)
enzyme confers resistance to the antibiotic
bialaphos (Wohlleben et al., 1988)
Event 59122 expresses the PAT protein,
which acetylates L-glufosinate-ammonium
and thereby confers tolerance to glufosinate
ammonium-based herbicides
MON810 Cry1Ab Based on a gene from Bacillus thuringiensis
subsp. kumamotoensis. B. thuringiensis is
an insect pathogen; its insecticidal activity
is attributed to the expression of crystal
protein (cry) genes (Schnepf et al., 1998)
Event MON810 expresses a cry1Ab gene
which was truncated at the 3’ end as a
result of the integration process. Cry1Ab is
a protein toxic to certain lepidopteran larvae
feeding on maize
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3.3.1.2. Integrity of the events in maize 1507 3 59122 3 MON810 3 NK6039
The genetic stability of the inserted DNA over multiple generations in the single maize events 1507,
59122, MON810 and NK603 was demonstrated previously (see Table 2). Integrity of these events in
maize 1507 9 59122 9 MON810 9 NK603 (F1 hybrid) was demonstrated by Southern analyses.
3.3.1.3. Information on the expression of the inserts10
Protein levels of Cry1F, PAT, Cry34Ab1, Cry35Ab1, Cry1Ab and CP4 EPSPS were analysed by
enzyme-linked immunosorbent assay (ELISA) in material harvested from ﬁeld trials across three
locations in the USA during the 2008 growing season. Samples analysed included leaf (R1), stalk (R1),
root (R1), pollen (R1) and grain (R6), both treated and not treated with glyphosate and glufosinate
ammonium.11 Grains and forage are the two main raw commodities used for food and feed purposes.
The GMO Panel requested protein expression data from forage, but the applicant did not provide this
information. In the absence of these data, the data on the levels of the newly expressed proteins in
leaves (R1) were used to estimate the levels in forage. However, although leaves are part of forage,
the developmental stage used for forage is usually not R1, therefore this estimation has a certain
degree of uncertainty. To reduce this uncertainty, the GMO Panel assessed the data available for
protein expression in forage and leaves from already assessed subcombinations (Table 2). The analysis
of these data showed that the levels of the newly expressed proteins in leaves (R1) were comparable
and in general higher than those in forage suggesting that, in this case, using data on expression
levels in leaves (R1) would not result in an underestimation of the expression levels in forage. The
highest mean values, regardless of the treatment, of the protein levels in grains and leaves of maize
1507 9 59122 9 MON810 9 NK603 are summarised in Table 5.
Event Protein
Donor organism and biological
function
Intended effects in GM plant
NK603 CP4 EPSPS Based on a gene from Agrobacterium strain
CP4. 5-enolpyruvyl-shikimate-3-phosphate
synthase (EPSPS) is an enzyme involved in
the shikimic acid pathway for aromatic
amino acid biosynthesis in plants and
microorganisms (Herrmann, 1995)
The bacterial CP4 EPSPS protein expressed
in maize NK603 confers tolerance to
glyphosate-containing herbicides as it has
lower afﬁnity towards glyphosate than the
plant endogenous enzyme
CP4 EPSPS
L214P
Donor organism: Agrobacterium sp. strain
CP4.
5-enopyruvyl-shikimate-3-phosphate
synthase (EPSPS) is an enzyme involved in
the shikimic acid pathway for aromatic
amino acid biosynthesis in plants and
microorganisms
Event NK603 expresses also CP4 EPSPS
L214P – this variant, compared to the CP4
EPSPS protein, contains a single amino acid
substitution from leucine to proline at
position 214. The two CP4 EPSPS protein
variants are structurally and functionally
equivalent
Table 5: Highest mean values and corresponding standard deviations and ranges of protein levels
(lg/g dry weight) in grain (n = 30) and leaves (n = 30) from maize 1507 9 59122 9
MON810 9 NK603
Protein
Tissue/Developmental stage
Grain/R6 Leaves/R1
Cry1F 4.3(b)  1.3(c) (NT)
2.5–8.7(d)
21  7.2 (T)
13–35
PAT 0.099  0.066 (T)
<LOQ–0.36
33  8.9 (T)
23–52
Cry34Ab1 33  10 (T)
12–51
110  46 (T)
53–190
Cry35Ab1 1.3  0.35 (NT)
0.69–2.2
81  20 (T)
42–130
9 Part I – Sections D.2 and D.5.
10 Part I – Section D.3.
11 Part I – Section D.3 and Annexes 4e and 4f.
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In order to assess changes in protein expression levels that may result from potential interactions
between the events, protein levels were determined for the four-event stack and the corresponding
single events in different parts of the plant.
The levels of all the newly expressed proteins in the four-event stack and the corresponding singles
were similar in all tissues except for the expected difference in PAT protein levels resulting from the
presence of two copies of the pat coding genes in the four-event stack (see Appendix A). Therefore,
there is no indication of interaction that may affect the levels of the newly expressed proteins in this
stack.
3.3.1.4. Conclusions of the molecular characterisation
The molecular data establish that the events stacked in maize 1507 9 59122 9 MON810 9 NK603
have retained their integrity. Protein expression analyses showed that the levels of the newly
expressed proteins are similar in the four-event stack and in the single events except for PAT which
showed the expected higher levels in the stack resulting from the combination of 1507 and 59122
(producing PAT) events. Therefore, there is no indication of an interaction between the events that
may affect their integrity and the levels of the newly expressed proteins in this stack.
Based on the known biological function of the newly expressed proteins, the only foreseeable
interactions at the biological level are between the Cry proteins in susceptible insects, which will be
dealt with in Section 3.3.4.4.
3.3.2. Comparative analysis
3.3.2.1. Choice of comparator and production of material for the comparative assessment12
Application EFSA-GMO-NL-2011-92 presents data on agronomic and phenotypic characteristics, as
well as on forage and grain composition of maize 1507 9 59122 9 MON810 9 NK603 from ﬁeld trials
performed at six sites in the USA during the 2008 growing season.
Maize 1507 9 59122 9 MON810 9 NK603 was obtained by conventional crossing of the four single
events. Events 1507, 59122 and NK603 were introduced in the inbred line PH09B, while event
MON810 was in inbred line PH581. As documented by the pedigree, the four single events were
combined in a hybrid maize with a genetic background (F1) of PH09B 9 PH581. The same two inbred
lines (PH09B and PH581) were crossed to produce the non-GM hybrid maize used as comparator. On
the basis of the provided pedigree, the GMO Panel considers that hybrid maize PH09B 9 PH581 is a
suitable non-GM comparator.
Field trials for the agronomic, phenotypic and compositional assessment of maize
1507 9 59122 9 MON810 9 NK603 were conducted at six sites in major maize growing areas in the
USA, representing regions of diverse agronomic practices and environmental conditions. At each site,
the following materials were grown in a randomised complete block design with three replicates: the
four-event stack maize and the non-GM comparator, both sprayed with plant protection products (PPP)
according to local requirements, and the four-event stack maize sprayed with the intended herbicides
(glyphosate and glufosinate-ammonium) on top of PPP. In addition, two ﬁeld trials were performed
with non-GM commercial maize varieties only. One was performed at six locations in the USA in 2003
Protein
Tissue/Developmental stage
Grain/R6 Leaves/R1
Cry1Ab 0.24  0.094 (NT)
0.096–0.54
24  4.4 (NT)
17–33
CP4 EPSPS(a) 14  3.2 (T)
6.3–20
190  34 (T)
130–270
T/NT: treated / not treated; <LOQ: Values below the limit of quantiﬁcation.
(a): CP4 EPSPS levels in the maize 1507 9 59122 9 MON810 9 NK603 are the sum of two protein variants, CP4 EPSPS and CP4
EPSPS L214P, expressed in NK603.
(b): Mean.
(c): Standard deviation.
(d): Range.
12 Part I – Sections D.7.1 and D.7.2.
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and included four13 non-GM commercial maize varieties,14 whereas the other was performed in the
USA (ﬁve sites) and Canada (one site) in 2007 with four15 commercial non-GM maize hybrids.16 Also,
in these two trials, a randomised complete block design with three replications was used. These ﬁeld
trials were used to collect agronomic, phenotypic and compositional data from non-GM commercial
varieties.
3.3.2.2. Agronomic and phenotypic analysis17,18
Fourteen traits related to crop physiology, morphology, development, yield and biotic stress were
measured.19 Data collected for 11 of the 14 parameters were subject to a formal statistical analysis.20
The other parameters (stalk lodging, root lodging and pollen viability) were not subject to a formal
statistical analysis because of the very low variability of the data (more than 80% of the data points
had the same value).
In the across-site analysis, no difference was observed between the four-event stack maize and the
non-GM comparator for nine of the 11 agronomic and phenotypic parameters. A signiﬁcant increase
was observed for early population in maize 1507 9 59122 9 MON810 9 NK603 (for both herbicides
regimes) compared to the non-GM comparator,21 and plant height was higher in maize
1507 9 59122 9 MON810 9 NK603 (not treated with the intended herbicides) than in the non-GM
comparator.22
The environmental impact of the observed differences in early population and plant height is
assessed in Section 3.3.4.
3.3.2.3. Compositional analysis23
Maize grain was analysed for 81 parameters24 and forage for 9 parameters,25 including the key
constituents recommended by the OECD (OECD, 2002). All the data were analysed statistically across
locations.26 When 80% or more of the analytical results for a speciﬁc constituent were below the limit
of quantiﬁcation, the constituent was omitted from the statistical analysis. In cases where a signiﬁcant
difference between maize 1507 9 59122 9 MON810 9 NK603 and the non-GM comparator was
identiﬁed, the level of the parameter in the four-stack maize was compared to the levels occurring in
the eight commercial non-GM maize varieties grown in the USA in 2003 and 2007.14,15
13 Non-GM hybrid maize: 34M94, 33G26, 33J24 and 3394.
14 Part I – Section D.7.2, Annex 7.
15 Non-GM hybrid maize: 38B85, 37Y12, 34A15 and 34P88.
16 Part I – Section D.7.2, Annex 8.
17 Part I – Section D7.4.
18 Additional information: 18/8/2014.
19 The following parameters were analysed: early population count, ﬁnal population count, seedling vigour, time to silking, time
to pollen shed, stalk lodging, root lodging, stay green, disease incidence, insect damage, pollen viability (shape and colour),
plant height and ear height.
20 A linear mixed model was ﬁtted: genotype was the ﬁxed effect, and the random effects were location and block-within-
location.
21 Mean value for early population for the non-GM comparator: 52 plants/plot; mean value for the GM (both herbicide regimes):
57 plants/plot.
22 Mean value for plant height for the non-GM comparator: 262 cm; mean value for the GM (sprayed with conventional
herbicides only): 273 cm.
23 Part I – Section D7.3, additional information: 18/8/2014.
24 The following parameters were measured in grain: crude protein, crude fat, crude ﬁbre, acid detergent ﬁbre (ADF), neutral
detergent ﬁbre (NDF), ash, carbohydrates, caprylic acid (C8:0), capric acid (C10:0), lauric acid (C12:0), myristic acid (C14:0),
myristoleic acid (C14:1), pentadecanoic acid (C15:0), pentadecenoic acid (C15:1), palmitic acid (C16:0), palmitoleic acid
(C16:1), heptadecanoic acid (C17:0), heptadecenoic acid (C17:1), heptadecadienoic acid (C17:2), stearic acid (C18:0), oleic
acid (C18:1), linoleic acid (C18:2), (9,15) isomer of linoleic acid (C18:2), linolenic acid (C18:3), c-linolenic acid (C18:3),
lignoceric acid, nonadecanoic acid (C19:0), arachidic acid (C20:0), eicosenoic acid (C20:1), eicosadienoic acid (C20:2),
eicosatrienoic acid (C20:3), arachidonic acid (C20:4), heneicosanoic acid (C21:0), behenic acid (C22:0), erucic acid (C22:1),
tricosanoic acid (C23:0), lignoceric acid (C24:0), methionine, cystine, lysine, tryptophan, threonine, isoleucine, histidine,
valine, leucine, arginine, phenylalanine, glycine, alanine, aspartic acid, glutamic acid, proline, serine, tyrosine calcium, copper,
iron, magnesium, manganese, phosphorus, potassium, sodium and zinc, beta-carotene, thiamin, riboﬂavin, niacin, pantothenic
acid, pyridoxine, folic acid, a-tocopherol, b-tocopherol, d-tocopherol, c-tocopherol, total tocopherols, inositol, furfural,
p-coumaric acid, ferulic acid, phytic acid, rafﬁnose and trypsin inhibitor.
25 The following parameters were measured in forage: crude protein, crude fat, ADF, crude ﬁbre, NDF, ash, carbohydrates,
calcium and phosphorus.
26 A linear mixed model was ﬁtted: genotype was the ﬁxed effect, and the random effects were location, block-within-location,
and genotype-by-location.
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In forage, signiﬁcant differences were observed for calcium and phosphorus between maize
1507 9 59122 9 MON810 9 NK603 not treated with the intended herbicides (untreated, Table 6) and
the non-GM comparator. Taking into account the well-known biological roles of these constituents, the
magnitude of the changes, the variability observed among non-GM commercial varieties in the 2003/2007
ﬁeld trials and the ranges for maize reported in the literature (OECD, 2002), the EFSA GMO
Panel concludes that these differences do not pose food and feed safety concerns.
Grains of maize 1507 9 59122 9 MON810 9 NK603 not treated with the intended herbicides
(untreated) were signiﬁcantly different from those collected the non-GM comparator for seven
parameters: the levels of linoleic acid and lignoceric acid were lower in the four-stack maize, while
crude fat, oleic acid, phosphorous, potassium and inositol were higher in the four-stack maize
(Table 6). The levels of all the signiﬁcantly different parameters observed in the four-stack maize fell
within the range of compositional values obtained from the 2003/2007 ﬁeld trials27 and from the
literature (OECD, 2002). Taking into account the known biological roles of these constituents, the
magnitude of the changes and the variability observed in the non-GM maize varieties, the GMO
Panel concluded that no further food and feed safety assessment is required.
Grains of maize 1507 x 59122 x MON810 x NK603 sprayed with the intended herbicides (treated) were
signiﬁcantly different from those collected the non-GM comparator for eight compounds (Table 6). These
were increased levels of crude fat, oleic acid, potassium and rafﬁnose, and reduced levels of linoleic acid,
lignoceric acid, manganese and zinc in maize 1507 9 59122 9 MON810 9 NK603 as compared to the
non-GM comparator. The levels of all the signiﬁcantly different parameters observed in the four-stack
maize fell within the range of compositional values obtained from the 2003/2007 ﬁeld trials20 and from
the literature (OECD, 2002). As for untreated maize 1507 9 59122 9 MON810 9 NK603, the EFSA GMO
Panel concluded that the differences observed did not require further food and feed safety assessment.
3.3.2.4. Conclusions of the comparative analysis
The EFSA GMO Panel concludes that none of the differences in agronomic and phenotypic
characteristics and composition of grain and forage identiﬁed between maize 1507 9 59122 9 MON810 9
NK603 and the non-GM comparator requires further assessment regarding food and feed safety.
Table 6: Compositional endpoints (means estimated from US 2008 ﬁeld trials data) for which
signiﬁcant differences (*) were found between maize 1507 9 59122 9 MON810 9 NK603
and the non-GM comparator PH09B 9 PH581 in forage and grain
Component
Maize
1507 3 59122 3
MON810 3 NK603 Non-GM comparator
Untreated Treated
Forage
Calcium [mg/kg dw] 2450* 2430 2250
Phosphorus [mg/kg dw] 2640* 2570 2410
Grain
Crude fat [% dw] 5.26* 5.28* 5.00
Phosphorus [mg/kg dw] 3260* 3150 3010
Potassium [mg/kg dw] 3210* 3110* 2920
Zinc [mg/kg dw] 16.5 16.1* 17.2
Manganese [mg/kg dw] 6.9 6.6* 7.3
Oleic acid [% of total fatty acids] 26.5* 26.0* 24.1
Linoleic acid [% of total fatty acids] 55.6* 55.8* 58.0
Lignoceric acid [% of total fatty acids] 0.212* 0.210* 0.242
Inositol [mg/kg dw] 204* 190 183
Rafﬁnose [mg/kg dw] 1510 1620* 1270
dw: dry weight.
27 Part I – Section D7.2, additional information: 18/8/2014 and 23/5/2016.
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The differences in early population and plant height identiﬁed between maize 1507 9 59122 9
MON810 9 NK603 and the non-GM comparator are further assessed for their potential environmental
impact in Section 3.3.4.
3.3.3. Food and feed safety assessment
3.3.3.1. Effects of processing28
Based on the outcome of the comparative assessment, processing of maize 1507 9 59122 9
MON810 9 NK603 into food and feed products is not expected to result in products being different
from those of commercial non-GM maize varieties.
3.3.3.2. Toxicology29
Toxicological assessment of newly expressed proteins30
Six proteins (Cry1F, Cry1Ab, Cry34Ab1, Cry35Ab1, PAT and CP4 EPSPS) are newly expressed in
maize 1507 9 59122 9 MON810 9 NK603 (Table 4). The GMO Panel has previously assessed these
proteins individually in the context of the single maize events and no safety concerns were identiﬁed
for humans or animals (Table 2). The GMO Panel is not aware of any new information that would
change these conclusions.
The potential for a functional interaction of these newly expressed proteins in maize
1507 9 59122 9 MON810 9 NK603 has been assessed with regard to human and animal health.
The two enzymatic proteins (PAT and CP4 EPSPS) catalyse distinct biochemical reactions and act on
unrelated substrates in the plant. The four insecticidal proteins (Cry1Ab, Cry34Ab1, Cry35Ab1 and Cry1F)
act through cellular receptors found in target insect species. It is reported that the gastrointestinal tract
of mammals, including humans, lacks receptors with speciﬁc high afﬁnity to Cry proteins (Hammond
et al., 2013; Koch et al., 2015).
On the basis of the known biological function of the newly expressed proteins (Table 4), there is
currently no expectation for possible interactions relevant to the food and feed safety assessment of
maize 1507 9 59122 9 MON810 9 NK603. No safety concerns were identiﬁed for the individual
proteins for humans and animals and the same conclusion can be extended to their presence in maize
1507 9 59122 9 MON810 9 NK603.
The EFSA GMO Panel concludes that there are no safety concerns to human and animal health
related to the newly expressed proteins Cry1Ab, Cry34Ab1, Cry35Ab1, Cry1F, PAT and CP4 EPSPS in
maize 1507 9 59122 9 MON810 9 NK603.
Toxicological assessment of components other than newly expressed proteins31
Maize 1507 9 59122 9 MON810 9 NK603 did not show any compositional difference to its non-GM
comparator that would require further assessment (see Section 3.3.2.3). No further food and feed
safety assessment of components other than newly expressed proteins is therefore required.
3.3.3.3. Animal studies with the food/feed derived from GM plants32
No substantial modiﬁcations in the composition of the four-event stack maize, no indication for
potential occurrence of unintended effects based on the preceding molecular, compositional or
phenotypic analyses, and no indication of possible interactions between the events were identiﬁed
(Sections 3.3.1, 3.3.2 and 3.3.3.2). Therefore, no animal studies on the food and feed derived from
maize 1507 9 59122 9 MON810 9 NK603 are required (EFSA, 2006a). Nevertheless, the EFSA GMO
Panel considered a 42-day study in broilers provided by the applicant.
A total of 720 (360 per sex) one-day old chickens for fattening (Ross 708 broilers) were randomly
allocated to six dietary groups with 120 chicks per treatment (12 pens per treatment, 10 birds per pen,
half for each sex) and fed diets containing milled grains (650–750 lm) from maize 1507 9
59122 9 MON810 9 NK603, either unsprayed (-Gly/Glu) or sprayed (+Gly/Glu) with a glyphosate-
glufosinate mixture (test items), or from an appropriate non-GM comparator (control item)
(Section 3.3.2.1) or one of three non-GM commercial varieties 33H25, 33M15 or 33D11 (reference items).
28 Part I – Section D.7.6.
29 Part I – Section D.7.8.
30 Part I – Section D.7.8.1.
31 Part I – Section D.7.8.2.
32 Part I – Section D.7.8.4.
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Event-speciﬁc PCR analysis on maize grains prior to diet formulation conﬁrmed the identity for
events 1507, 59122, MON810 and NK603 of test grains and the lack of contamination in the non-GM
comparator and non-GM commercial varieties. Low levels of event NK603 were however detected in
reference maize 33H25 and 33D11. Newly expressed proteins (Cry1F, Cry34Ab1, Cry35Ab1, PAT,
Cry1Ab and CP4 EPSPS) were also analysed in maize grains by ELISA. Test, control and reference
materials were analysed for proximates, amino acids and mycotoxins and the metabolizable energy
was calculated for each maize lot.
Starter (0–21 days), grower (22–35 days) and ﬁnisher (36–42 days) diets contained 63%, 67.5% and
74% milled maize grains, respectively, and were balanced to meet nutrient requirements of broilers.
Newly expressed proteins (Cry1F, Cry34Ab1, Cry35Ab1, PAT, Cry1Ab and CP4 EPSPS) in test diets were
used to conﬁrm (ELISA test) diet homogeneity and stability of these proteins. Diets were sampled for
proximate analysis (including calcium and phosphorus), gross energy and amino acid analysis. Diets (as
mash feed) and water were offered ad libitum from day of hatching. Chickens were monitored three times
daily for health status and mortality; body weight and feed intake were recorded weekly; body weight
gain, feed intake, and mortality-adjusted feed:gain ratio (feed efﬁciency) were calculated for Days 0–42.
At the end of the feeding period, all survived birds were sacriﬁced and eight birds per pen (half for
each sex) were randomly selected and processed in order to determine liver and kidney weight and
post-chilled carcass yield, both as percentages of whole live bird weight and cuttable parts (i.e. thighs,
breasts, wings, legs, abdominal fat including fat around gizzard) yield, as the percentage of post-chill
dressed carcass weight.
No signiﬁcant differences in mortality (about 2%), ﬁnal body weight, weight gain, feed to gain
ratio, and yield of pre-chill organs and post-chilled carcass and cuttable part percentages assessed
were observed between the groups fed diets containing the four-event stack maize (treated with the
intended herbicide or not) or the non-GM comparator (tailored mixed models of analysis of variance).
The GMO Panel concludes that administration of diets containing up to 74% of maize grain
1507 9 59122 9 MON810 9 NK603 to broilers, up to 42 days, did not cause adverse effects.
Moreover, the measured performance endpoints were similar between groups fed balanced diets
containing GM and non-GM comparator.
3.3.3.4. Allergenicity33
For allergenicity assessment, a weight-of-evidence approach was followed, taking into account all of
the information on the newly expressed proteins, since no single piece of information or experimental
method yields sufﬁcient evidence to predict allergenicity (EFSA, 2006a; Codex Alimentarius, 2009). In
addition, when known functional aspects of the newly expressed protein or structural similarity to
known adjuvants may indicate an adjuvant activity, the possible role of these proteins as adjuvants is
considered (EFSA GMO Panel, 2011a). When newly expressed proteins with a potential adjuvant
activity are expressed together, possible interactions increasing adjuvanticity and impacting the
allergenicity of the GM crop are assessed.
Assessment of allergenicity of the newly expressed proteins34
The GMO Panel previously evaluated the safety of the Cry1F, Cry34Ab1, Cry35Ab1, PAT, Cry1Ab and
CP4 EPSPS proteins individually, and no concerns on allergenicity were identiﬁed (Table 2). No new
information on allergenicity of the single events that might change the previous conclusions has
become available. Based on current knowledge and since none of the newly expressed proteins
showed allergenicity, no reasons for concern regarding the presence of these newly expressed proteins
in this four-event stack maize affecting allergenicity were identiﬁed.
For adjuvanticity, proteins derived from B. thuringiensis (Bt proteins) have been suggested to
possess adjuvant activity, based on animal studies on Cry1Ac when applied at relatively high doses
(e.g. Vazquez et al., 1999). The Panel has previously evaluated the safety of Cry1F, Cry34Ab1,
Cry35Ab1 and Cry1Ab proteins and no concerns on adjuvanticity in the context of the applications
assessed were identiﬁed (Table 2). The levels of Bt proteins in this four-event stack maize are similar
to those in the respective single maize events (see Table 5). From the limited experimental evidence
available, the GMO Panel did not ﬁnd indications that the presence of the Bt proteins at the levels
expressed in this four-event stack maize might act as adjuvants with the potential to enhance a
speciﬁc immunoglobulin E (IgE) response and to favour the development of an allergic reaction.
33 Part I – Section D.7.9.
34 Part I – Section D.7.9.1.
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Assessment of allergenicity of GM plant products35
The GMO Panel regularly reviews the available publications on food allergy to maize. However, to
date, maize has not been considered a common allergenic food36 (OECD, 2002). Therefore, the EFSA
GMO Panel did not request experimental data to analyse the allergen repertoire of GM maize.
In the context of this application and considering the data from the molecular characterisation, the
compositional analysis and the assessment of the newly expressed proteins (Sections 3.3.2 and
3.3.3.2), the GMO Panel identiﬁed no indications of a potentially increased allergenicity of food and
feed derived from the four-event stack maize compared to that derived from its non-GM comparator.
3.3.3.5. Nutritional assessment of GM food/feed37
The intended trait of the four-event stack maize 1507 9 59122 9 MON810 9 NK603 is insect
resistance and herbicide tolerance, with no intention to alter nutritional parameters.
The comparison of grain and forage composition between the four-event stack with its non-GM
comparator did not identify differences that would require a nutritional assessment as regards to food
and feed (Section 3.3.2.4).
From these data, the nutritional characteristics of the food and feed derived from this four-event
stack maize are not expected to differ from those of food and feed derived from its non-GM comparator
and non-GM commercial varieties. This was conﬁrmed by a feeding study in broilers (Section 3.3.3.3).
3.3.3.6. Conclusion of the food and feed safety assessment
The newly expressed proteins in the four-event stack maize 1507 9 59122 9 MON810 9 NK603 do
not raise safety concerns for human and animal health. No interactions between these proteins
relevant for food and feed safety were identiﬁed. Similarly, the GMO Panel did not identify indications
of safety concerns regarding allergenicity or adjuvanticity related to the presence of newly expressed
proteins in this four-event stack maize, or regarding the overall allergenicity of this four-event stack
maize. Maize 1507 9 59122 9 MON810 9 NK603 is as nutritious as the non-GM comparator.
3.3.4. Environmental risk assessment
Considering the scope of the application EFSA-GMO-NL-2011–92, which excludes cultivation, the
environmental risk assessment (ERA) of maize 1507 9 59122 9 MON810 9 NK603 is mainly concerned
with: (1) the exposure of bacteria to recombinant DNA in the gastrointestinal tract of animals fed GM
material and bacteria present in environments exposed to faecal material of these animals (manure and
faeces) and (2) the accidental release into the environment of viable maize 1507 9
59122 9 MON810 9 NK603 grains during transportation and/or processing (EFSA GMO Panel, 2010).
3.3.4.1. Persistence and invasiveness of the GM plant38
Maize is highly domesticated, not winter hardy in colder regions of Europe, and generally unable to
survive in the environment without appropriate management. Occasional feral GM maize plants may
occur outside cultivation areas in the EU (e.g. Pascher, 2016), but survival is limited mainly by a
combination of low competitiveness, absence of a dormancy phase and susceptibility to plant
pathogens, herbivores and cold climate conditions (OECD, 2002). Field observations indicate that maize
grains may survive and overwinter in some EU regions, resulting in volunteers in subsequent crops (e.g.
Gruber et al., 2008; Palaudelmas et al., 2009; Pascher, 2016). However, maize volunteers have been
shown to grow weakly and ﬂower asynchronously with the maize crop (Palaudelmas et al., 2009). Thus,
the establishment and survival of feral and volunteer maize in the EU is currently limited and transient.
It is unlikely that the intended traits of maize 1507 9 59122 9 MON810 9 NK603 will provide a
selective advantage to maize plants, except when they are exposed to glufosinate-ammonium and/or
glyphosate-containing herbicides or infested by insect pests that are susceptible to the Cry1Ab, Cry1F
or Cry34/35Ab1 proteins.
The GMO Panel considers that the ﬁtness advantage provided by the intended traits, and the
observed agronomic and phenotypic differences in early population and plant height (see
35 Part I – Section D.7.9.2
36 Directive 2007/68/EC of the European Parliament and of the Council of 27 November 2007 amending Annex IIIa to Directive
2000/13/EC of the European Parliament and of the Council as regards certain food ingredients. OJ L 310, 27.11.2007, p. 11–14.
37 Part I – Section D.7.10.
38 Part I—Section D.9.1
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Section 3.3.2.2) will not allow the GM plant to overcome other biological and abiotic factors (described
above) limiting plant’s persistence and invasiveness. Therefore, the presence of the intended traits and
other observed differences will not affect the persistence and invasiveness of the GM plant.
In conclusion, the GMO Panel considers very unlikely that maize 1507 9 59122 9 MON810 9 NK603
will differ from conventional maize hybrid varieties in its ability to survive until subsequent seasons, or to
establish occasional feral plants under European environmental conditions in case of accidental release
into the environment of viable maize 1507 9 59122 9 MON810 9 NK603 grains.
3.3.4.2. Potential for gene transfer39
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either through horizontal gene transfer of DNA, or through vertical gene ﬂow via cross-
pollination from feral plants originating from spilled grains.
Plant-to-microorganism gene transfer
The potential for horizontal adverse effects of horizontal gene transfer of the recombinant DNA
have been assessed for the single events in previous GMO Panel Scientiﬁc Opinions (see in Table 2).
No concern as a result of an unlikely, but theoretically possible, horizontal gene transfer of the
recombinant genes to bacteria in the gut of animal fed GM material or other receiving environments
was identiﬁed. Synergistic effects of the recombinant genes, for instance due to combinations of
recombinogenic sequences, which would cause an increase in the likelihood for horizontal gene
transfer or a selective advantage were not identiﬁed. Therefore, the EFSA GMO Panel concludes that
the unlikely, but theoretically possible, horizontal transfer of recombinant genes from this four-event
stack maize to bacteria does not raise any environmental safety concern.
Plant-to plant-gene transfer
The potential for occasional feral GM maize 1507 9 59122 9 MON810 9 NK603 plants originating
from grain import spills to transfer recombinant DNA to sexually compatible plants and the
environmental consequences of this transfer were considered.
For plant-to-plant gene transfer to occur, imported GM maize grains need to germinate and develop
into plants in areas containing sympatric wild relatives and/or cultivated maize with synchronous
ﬂowering and environmental conditions favouring cross-pollination.
Vertical gene transfer from maize is limited to Zea species. Wild relatives of maize outside
cultivation are not known/reported in Europe (Eastham and Sweet, 2002; OECD, 2003; EFSA, 2016;
Trtikova et al., 2017). Therefore, potential vertical gene transfer is restricted to maize and weedy Zea
species, such as teosintes, and/or maize-teosinte hybrids, occurring in cultivated areas (EFSA, 2016,
Trtikova et al., 2017).
The potential of spilled maize grains to establish, grow and produce pollen is extremely low and
transient (see Section 3.3.4.1). The likelihood/frequency of cross-pollination between occasional feral
GM maize plants resulting from grain spillage, and weedy or cultivated Zea plants is considered
extremely low. Even if cross-pollination would occur, the GMO Panel is of the opinion that
environmental effects as a consequence of the spread of genes from occasional feral GM maize plants
in Europe will not differ from that of conventional maize varieties for the reasons given in
Section 3.3.4.1, even in the case of treatment with the intended herbicides.
3.3.4.3. Interactions of the GM plant with target organisms40
Taking the scope of the application EFSA-GMO-NL-2011-92 into account, potential interactions of
occasional feral maize 1507 9 59122 9 MON810 9 NK603 plants arising from grain import spills with
the target organisms are not considered a relevant issue by the GMO Panel.
3.3.4.4. Interactions of the GM plant with non-target organisms41
Given that environmental exposure of non-target organisms to spilled GM grains or occasional feral
GM maize plants arising from spilled GM grains is limited and because most proteins are degraded
before entering the environment through faecal material of animals fed GM maize, potential
interactions of maize 1507 9 59122 9 MON810 9 NK603 with non-target organisms are not
39 Part I—Section D 9.3 and additional information: 19/11/2015 and 09/6/2017.
40 Part I – Section D9.4.
41 Part I – Section E3.4.
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considered a relevant issue by the GMO Panel. Interactions that may occur between the Cry proteins
(as mentioned in Section 3.3.1.1) will not alter this conclusion.
3.3.4.5. Interactions with the abiotic environment and biogeochemical cycles42
Given that environmental exposure to spilled grains or occasional feral maize 1507 9
59122 9 MON810 9 NK603 plants arising from grain import spills is limited and because most proteins
are degraded before entering the environment through faecal material of animals fed GM maize,
potential interactions with the abiotic environment and biogeochemical cycles are not considered a
relevant issue by the GMO Panel.
3.3.4.6. Conclusion of the environmental risk assessment
The GMO Panel concludes that it is unlikely that maize 1507 9 59122 9 MON810 9 NK603 would
differ from conventional maize varieties in its ability to persist under the EU environmental conditions.
Considering the scope of the application EFSA-GMO-NL-2011-92, interactions of occasional feral maize
1507 9 59122 9 MON810 9 NK603 plants with the biotic and abiotic environment are not considered
to be relevant issues. The analysis of horizontal gene transfer from this four-stack maize to bacteria
does not indicate a safety concern. Therefore, considering the combined traits and their interactions,
the outcome of the comparative analysis, the routes and levels of exposure, the GMO Panel concludes
that maize 1507 9 59122 9 MON810 9 NK603 would not raise safety concerns in the event of
accidental release of viable GM maize grains into the environment.
3.3.5. Conclusion on maize 1507 3 59122 3 MON810 3 NK603
No new data on the single maize events 1507, 59122, MON810 and NK603 leading to a
modiﬁcation of the original conclusions on their safety were identiﬁed.
The combination of events 1507, 59122, MON810 and NK603 in the four-event stack maize does
not raise issues relating to molecular, agronomic/phenotypic or compositional characteristics that would
require further investigation in terms of food and feed safety and nutrition.
The newly expressed proteins in the four-event stack maize do not raise safety concerns for human
and animal health and the environment, in light of the scope of this application.
No indications of interactions between the events based on the biological functions of the newly
expressed proteins that would raise a safety issue were identiﬁed in maize 1507 9 59122 9
MON810 9 NK603. Comparison of the levels of the newly expressed proteins between the four-event
stack and each of the single events did not reveal an interaction at protein expression level.
Considering the combined traits and the outcome of the comparative analysis, and routes and
levels of exposure, the GMO Panel concludes that maize 1507 9 59122 9 MON810 9 NK603 would
not raise safety concerns in the event of accidental release of viable GM maize grains into the
environment.
No scientiﬁc information that could change the conclusions on this four-event stack was retrieved in
a literature search covering the period since the time of validity of the application.43 The GMO
Panel concludes that the four-event stack maize is as safe and as nutritious as its non-GM comparator
in the context of its scope.
3.4. Risk assessment of the subcombinations
Subcombinations previously assessed in the frame of other applications are discussed in
Section 3.4.1.
The strategy followed for the assessment of those subcombinations for which no speciﬁc data have
been submitted and which have not been previously assessed by the GMO Panel (Table 1), has been
described by the GMO Panel.44 In this case, the risk assessment takes as its starting point the
assessment of the single maize events, and uses the data generated for the four-event stack, as well
as all the additional data available on subcombinations previously assessed by the GMO Panel.
42 Part I – Section E3.6.
43 Additional information: 7/7/2016 and 9/6/2017.
44 115th GMO Panel meeting (Annex 1 of the minutes: http://www.efsa.europa.eu/sites/default/files/event/170517-m.pdf).
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3.4.1. Subcombinations previously assessed
The two-event stack maize 1507 9 59122, 1507 9 NK603, 59122 9 NK603 and
NK603 9 MON810, and the three-event stack maize 59122 9 1507 9 NK603 have been assessed
previously by the GMO Panel, and no safety concerns were identiﬁed (Table 1). A literature search
revealed no new scientiﬁc information relevant to the risk assessment of these stack maize that
became available since the validation of the application EFSA-GMO-NL-2011-92.45 Consequently, the
GMO Panel considers that its previous conclusions on these subcombinations remain valid.
3.4.2. Subcombinations not previously assessed
Five subcombinations of maize 1507 9 59122 9 MON810 9 NK603 have not been previously
assessed: the two-event stack maize 1507 9 MON810 and 59122 9 MON810 and the three-event
stacks 1507 9 59122 9 MON810, 1507 9 MON810 9 NK603 and 59122 9 MON810 9 NK603.
Experimental data for four of these subcombinations (1507 9 MON810, 59122 9 MON810,
1507 9 59122 9 MON810, and 1507 9 MON810 9 NK603) were provided in this application and are
further discussed in Section 3.4.2.2. A literature search revealed no scientiﬁc information relevant to
the risk assessment of these subcombinations that became available since the validation of this
application.44
3.4.2.1. Stability of the events
The genetic stability of the inserted DNA over multiple generations in the four single maize events was
demonstrated previously (Table 2). Integrity of the events was demonstrated in maize 1507 9 59122 9
MON810 9 NK603 (Section 3.3.1.2) and in previously assessed maize subcombinations (Table 2). The
GMO Panel ﬁnds no reasons to expect the loss of integrity of the events in the maize subcombinations not
previously assessed.
3.4.2.2. Expression of the events
Protein expression levels were measured for the newly expressed proteins in two subcombinations,
maize 59122 9 MON810 and maize 1507 9 MON810 9 NK603, in material harvested from plants
grown in the same ﬁeld trials as maize 1507 9 59122 9 MON810 9 NK603 (described in
Section 3.3.1.3). For all tissues, the levels of the newly expressed proteins in these two
subcombinations were similar to the levels observed in the singles and those observed in the four-
event stack maize except for PAT, which showed the expected higher levels in the four-event stack
resulting from the combination of events 1507 and 59122 both producing PAT protein.46 From these
data, there is no indication of an interaction that may affect the levels of the newly expressed proteins
in these subcombinations.
Protein expression data obtained from a greenhouse study were provided for maize
1507 9 MON810, 59122 9 MON810 and 1507 9 59122 9 MON810. These data did not indicate any
interactions that may affect protein expression level; however, the GMO Panel notes that greenhouse
experiments are not considered as informative as ﬁeld trials.47
The analysis of the levels of the newly expressed proteins in four out of the ﬁve subcombinations of
maize 1507 9 59122 9 MON810 9 NK603 did not indicate interactions that may affect their
expression. The GMO Panel considered that based on these data, and on current knowledge of the
molecular elements introduced, there is no reason to expect interactions that would affect the levels of
the newly expressed proteins in the subcombination for which no data were provided.
This assumption was further conﬁrmed by comparing the levels of the newly expressed proteins of
each single maize event with those of the four-event stack maize. The levels were similar in the four-
stack maize and in the single events except for PAT, which showed the expected higher levels in the
stack resulting from the combination of events 1507 and 59122 both producing PAT protein
(Section 3.3.1.3 and Appendix A). Therefore, there was no indication of an interaction manifesting at
protein expression level. In addition, expression data from the two-event stacks maize 1507 9 59122,
1507 9 NK603, 59122 9 NK603 and NK603 9 MON810 (EFSA, 2005d, 2006b, 2008, 2009d) and the
three-event stack maize 59122 9 1507 9 NK603 (EFSA, 2009e) were similar to those observed in
each of the single maize events or showed the expected higher levels for PAT resulting from the
45 Additional information: 9/6/2017.
46 Annexes 4a–d
47 Annex 5
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combination of 1507 and 59122 events both producing PAT protein. This conﬁrms that interactions
affecting expression levels of the newly expressed proteins are not expected in the ﬁve maize
subcombinations not previously assessed and included in the scope of application EFSA-GMO-NL-2011-
92.
3.4.2.3. Potential interactions between the events
The GMO Panel assessed the potential for interactions between events, due to their combination in
the two-event stack maize 1507 9 MON810 and 59122 9 MON810; and the three-event stacks
1507 9 59122 9 MON810, 1507 9 MON810 9 NK603 and 59122 9 MON810 9 NK603, taking into
consideration the intended traits and potential unintended effects.
Based on the known biological functions of the individual newly expressed proteins (Table 4), there is
currently no expectation for possible interactions between these proteins in maize 1507 9 MON810;
59122 9 MON810; 1507 9 59122 9 MON810; 1507 9 MON810 9 NK603 and 59122 9 MON810 9 NK603
relevant for the food/feed or environmental safety.
The GMO Panel took into account the intended and any potential unintended effects considered in
the assessment of the four single events, of the two-event stack maize 1507 9 59122, 1507 9 NK603,
59122 9 NK603 and NK603 9 MON810 and the three-event stack maize 59122 9 1507 9 NK603. It
was concluded that none of these effects would raise safety concerns when combined in any of these
maize subcombinations. Therefore, the GMO Panel is of the opinion that no additional data are needed
to complete the assessment of subcombinations of the four-event stack maize.
3.4.3. Conclusion
Maize 1507 9 59122 9 MON810 9 NK603 has 10 possible subcombinations, of which ﬁve have
been previously assessed (Table 2). Since no new safety concerns were identiﬁed for these previously
assessed two-event and three-event stack maizes, the GMO Panel considers that its previous
conclusions on these subcombinations remain valid.
The remaining ﬁve subcombinations included in the scope of application EFSA-GMO-NL-2011-92
were not previously assessed. For four of these subcombinations protein expression data were
provided and did not indicate an interaction affecting the levels of the newly expressed proteins. The
GMO Panel assessed the possibility of interactions between the events in these ﬁve subcombinations
and concluded that these combinations would not raise safety concerns. The ﬁve subcombinations not
previously assessed are expected to be as safe as the single maize events, the previously assessed
two-event stack maize 1507 9 59122, 1507 9 NK603, 59122 9 NK603 and NK603 9 MON810, the
three-event stack maize 59122 9 1507 9 NK603, as well as the four-event stack maize
1507 9 59122 9 MON810 9 NK603.
3.5. Post-market monitoring
3.5.1. Post-market monitoring of GM food/feed
No relevant compositional, agronomic and phenotypic changes were identiﬁed in maize
1507 9 59122 9 MON810 9 NK603 when compared with the non-GM comparator. Furthermore, the
overall intake or exposure is not expected to change because of the introduction of maize
1507 9 59122 9 MON810 9 NK603 into the market.
The two-event maize stacks 1507 9 59122, 1507 9 NK603, 59122 9 NK603 and NK603 9
MON810 and the three-event stack maize 59122 9 1507 9 NK603 have been previously assessed and
no safety concerns were identiﬁed. The ﬁve subcombinations not previously assessed and included in
the scope of application EFSA-GMO-NL-2011-92 are expected to be as safe as the single maize events,
the previously assessed maize subcombinations and the four-event stack maize
1507 9 59122 9 MON810 9 NK603. Therefore, the GMO Panel considers that post-market monitoring
of maize 1507 9 59122 9 MON810 9 NK603 and its subcombinations is not necessary.
3.5.2. Post-market environmental monitoring
The objectives of a PMEM plan, according to Annex VII of Directive 2001/18/EC are: (1) to conﬁrm
that any assumption regarding the occurrence and impact of potential adverse effects of the GMO, or
its use, in the ERA are correct and (2) identify the occurrence of adverse effects of the GMO, or its
use, on human health or the environment that were not anticipated in the ERA.
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Monitoring is related to risk management, and thus a ﬁnal adoption of the PMEM plan falls outside
the mandate of EFSA. However, the GMO Panel gives its opinion on the scientiﬁc methodology of the
PMEM plan provided by the applicant (EFSA GMO Panel, 2011b).
As the ERA did not identify potential adverse environmental effects from the maize
1507 9 59122 9 MON810 9 NK603, no case-speciﬁc monitoring is required.
The PMEM plan proposed by the applicant for maize 1507 9 59122 9 MON810 9 NK603 includes:
(1) the description of a monitoring approach involving operators (federations involved in import and
processing), reporting to the applicants, via a centralised system, any observed adverse effect(s) of
GMOs on human health and the environment; (2) a coordinating system established by EuropaBio for
the collection of information recorded by the various operators and (3) the review of relevant scientiﬁc
publications retrieved from literature searches (Lecoq et al., 2007; Windels et al., 2008). The applicant
proposes to submit a PMEM report on an annual basis and a ﬁnal report at the end of the
authorisation period.
The EFSA GMO Panel considers that the scope of the PMEM plan provided by the applicant is consistent
with the intended uses of maize 1507 9 59122 9 MON810 9 NK603 and its subcombinations. The EFSA
GMO Panel agrees with the reporting intervals proposed by the applicant in its PMEM plan.
4. Overall conclusions and recommendations
No new information on the four single maize events 1507, 59122, MON810 and NK603 leading to a
modiﬁcation of the original conclusions on their safety were identiﬁed.
The combination of events 1507, 59122, MON810 and NK603 in the four-event stack maize did not
give rise to issues relating to molecular, agronomic/phenotypic and compositional characteristics
regarding food and feed safety. The newly expressed proteins in the four-event stack maize did not
raise concerns for human and animal health. The compositional data indicated that maize
1507 9 59122 9 MON810 9 NK603 is expected to be as nutritious as its non-GM comparator.
The GMO Panel concludes that maize 1507 9 59122 9 MON810 9 NK603 is as safe and as
nutritious as its non-GM comparator in the context of the scope of this application.
The GMO Panel concluded that there is a very low likelihood of environmental effects resulting from
the accidental release of viable grains from maize 1507 9 59122 9 MON810 9 NK603 into the
environment.
Since no new data on the ﬁve previously assessed subcombinations of maize 1507 9 59122 9
MON810 9 NK603 that would lead to a modiﬁcation of the original conclusions on their safety were
identiﬁed, the GMO Panel considers that its previous conclusions on these maize stacks remain valid.
Five subcombinations were not previously assessed. For four of these subcombinations, protein
expression data were provided and did not indicate an interaction affecting the levels of the newly
expressed proteins. The GMO Panel assessed the possibility of interactions between the events in the
ﬁve subcombinations not previously assessed and concluded that these combinations would not raise
safety concerns. The ﬁve subcombinations not previously assessed are expected to be as safe as the
single maize events, the previously assessed two-event stack maize 1507 9 59122, 1507 9 NK603,
59122 9 NK603 and NK603 9 MON810, the three-event stack maize 59122 9 1507 9 NK603, as well
as the four-event stack maize 1507 9 59122 9 MON810 9 NK603.
Given the absence of safety concerns for food and feed derived from maize 1507 9 59122 9
MON810 9 NK603 and its subcombinations, the GMO Panel considers that post-market monitoring of
these products is not necessary. The PMEM plan and reporting intervals are in line with the intended
uses of maize 1507 9 59122 9 MON810 9 NK603 and its subcombinations.
Documentation provided to EFSA
1) Letter from the Competent Authority of the Netherlands received on 3 February 2011 concerning
a request for placing on the market of genetically modiﬁed maize 1507 9 59122 9 MON
810 9 NK603 submitted by Pioneer Overseas Corporation in accordance with Regulation (EC)
No 1829/2003 (application reference EFSA-GMO-NL-2011-92).
2) Acknowledgement letter dated 15 February 2011 from EFSA to the Competent Authority of
the Netherlands.
3) Letter from EURL-GMFF dated 21 February 2011 requesting additional information under
completeness check.
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4) Letter from EFSA to applicant dated 30 March 2011 requesting additional information under
completeness check.
5) Letter from applicant to EFSA received on 17 May 2011 providing additional information
under completeness check.
6) Letter from EURL-GMFF dated 26 May 2011 requesting additional information under
completeness check.
7) Letter from EFSA to applicant dated 9 June 2011 requesting additional information under
completeness check.
8) Letter from applicant to EFSA received on 8 August 2011 providing clariﬁcations.
9) Letter from EURL-GMFF dated 30 September 2011 requesting additional information under
completeness check.
10) Letter from applicant to EFSA received on 25 October 2011 providing additional information
under completeness check.
11) Letter from EFSA to applicant dated 22 November 2011 requesting additional information
under completeness check.
12) Letter from applicant to EFSA received on 9 January 2012 providing additional information
under completeness check.
13) Letter from EFSA to applicant dated 30 January 2012 delivering the ‘Statement of Validity’
of application EFSA-GMO-NL-2011-92 for placing on the market of genetically modiﬁed
maize 1507 9 59122 9 MON 810 9 NK603 submitted by Pioneer Overseas Corporation in
accordance with Regulation (EC) No 1829/2003.
14) Letter from EURL-GMFF to EFSA dated 22 February 2012 requesting EFSA to stop the clock.
15) Letter from EFSA to applicant dated 1 March 2012 requesting additional information (EURL-
GMFF) and stopping the clock.
16) Letter from EFSA to applicant dated 13 April 2012 requesting additional information and
maintaining the clock stopped.
17) Letter from applicant to EFSA received on 31 May 2012 providing additional information.
18) Letter from EFSA to applicant dated 11 July 2012 requesting additional information and
maintaining the clock stopped.
19) Letter from applicant to EFSA received on 14 August 2012 extending the timeline for
submission of responses.
20) Letter from EFSA to applicant dated 24 September 2012 requesting additional information
and maintaining the clock stopped.
21) Letter from applicant to EFSA received on 2 October 2012 providing additional information.
22) Letter from applicant to EFSA received on 7 November 2012 extending the timeline for
submission of responses.
23) Letter from applicant to EFSA received on 10 December 2012 providing additional
information.
24) Letter from EURL-GMFF to EFSA dated 11 December 2012 requesting EFSA to re-start the
clock.
25) Letter from EFSA to applicant dated 9 January 2013 requesting additional information and
maintaining the clock stopped.
26) Letter from applicant to EFSA received on 20 February 2013 providing additional
information.
27) Letter from EFSA to applicant, dated 23 October 2013, re-starting the clock.
28) Letter from EFSA to applicant dated 7 January 2014 requesting additional information and
stopping the clock.
29) Letter from EFSA to applicant dated 14 March 2014 requesting additional information and
maintaining the clock stopped.
30) Letter from applicant to EFSA received on 8 April 2014 extending the timeline for
submission of responses.
31) Letter from applicant to EFSA received on 6 May 2014 providing additional information.
32) Letter from EFSA to applicant dated 13 June 2014 requesting additional information and
maintaining the clock stopped.
33) Letter from applicant to EFSA received on 4 July 2014 extending the timeline for submission
of responses.
34) Letter from applicant to EFSA received on 6 August 2014 providing additional information.
35) Letter from applicant to EFSA received on 18 August 2014 providing additional information.
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36) Letter from EFSA to applicant dated 27 October 2014 requesting additional information and
maintaining the clock stopped.
37) Letter from EFSA to applicant dated 15 December 2014 requesting additional information
and maintaining the clock stopped.
38) Letter from applicant to EFSA received on 5 February 2015 providing additional information.
39) Letter from applicant to EFSA received on 7 April 2015 extending the timeline for
submission of responses.
40) Letter from applicant to EFSA received on 7 October 2015 extending the timeline for
submission of responses.
41) Letter from applicant to EFSA received on 19 November 2015 providing additional
information.
42) Letter from applicant to EFSA received on 25 November 2015 providing additional
information.
43) Letter from EFSA to applicant dated 11 December 2015 requesting additional information
and maintaining the clock stopped.
44) Letter from applicant to EFSA dated 10 March 2016 extending the timeline for submission
of responses.
45) Letter from applicant to EFSA dated 7 April 2016 extending the timeline for submission of
responses.
46) Letter from applicant to EFSA received on 23 May 2016 providing additional information.
47) Email from EFSA to applicant, dated 31 May 2016, re-starting the clock from 23 May 2016.
48) Letter from EFSA to applicant dated 1 June 2016 requesting additional information and
stopping the clock.
49) Letter from applicant to EFSA received on 7 July 2016 providing additional information.
50) Email from EFSA to applicant, dated 8 July 2016, re-starting the clock from 7 July 2016.
51) Letter from EFSA to applicant dated 07 July 2015 requesting additional information and
stopping the clock.
52) Letter from EFSA to applicant dated 3 August 2016 requesting additional information and
stopping the clock.
53) Letter from applicant to EFSA received on 12 October 2016 providing additional
information.
54) Email from EFSA to applicant, dated 13 October 2016, re-starting the clock from 12 October
2016.
55) Letter from EFSA to applicant dated 17 October 2016 requesting additional information and
stopping the clock.
56) Letter from applicant to EFSA dated 25 November 2016 extending the timeline for
submission of responses.
57) Letter from applicant to EFSA received on 23 January 2017 providing additional information.
58) Email from EFSA to applicant, dated 24 January 2017, re-starting the clock from 23 January
2017.
59) Letter from EFSA to applicant dated 8 March 2017 requesting additional information and
stopping the clock.
60) Letter from EFSA to applicant dated 18 May 2017 requesting additional information and
maintaining the clock stopped.
61) Letter from applicant to EFSA received on 9 June 2017 providing additional information.
62) Letter from applicant to EFSA dated 30 June 2017 extending the timeline for submission of
responses.
63) Letter from applicant to EFSA received on 21 August 2017 providing additional information.
64) Email from EFSA to applicant, dated 22 August 2017, re-starting the clock from 21 August
2017
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Abbreviations
CaMV cauliﬂower mosaic virus
Cry crystal protein
CTP chloroplast transit peptide
dw dry weight
ELISA enzyme-linked immunosorbent assay
EPSPS 5-enolpyruvylshikimate-3-phosphate synthase
ERA environmental risk assessment
GM genetically modiﬁed
GMO genetically modiﬁed organism
GMO Panel EFSA Panel on Genetically Modiﬁed Organisms
IgE immunoglobulin E
LOQ limit of quantiﬁcation
ORF open reading frame
PAT phosphinothricin acetyl transferase
PMEM post-market environmental monitoring
PPP plant protection product
UTR untranslated region
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Appendix A – Protein expression data
Means, standard deviation and ranges of protein levels (lg/g dry weight) from maize
1507 9 59122 9 MON810 9 NK603, 1507, 59122, MON810 and NK603 from ﬁeld trials performed in
USA in 200848
1507 3 59122 3
MON810 3 NK603
1507 59122 MON810 NK603
Cry1F
Pollen (R1) 26(a)  3.7(b)
19–34(c)
26  3.6
20–35
Leaf (R1) 18  4.1
11–25
19  3.8
13–29
Stalk (R1) 7.4  0.83
6.4–9.4
7.7  0.71
6.0–9.4
Root (R1) 4.1  1.7
1.2–6.6
4.0  1.7
1.4–6.9
Grain(R6) 4.3  1.3
2.5–8.7
4.3  1.4
<LOQ–6.9
Cry34Ab1
Pollen (R1) 58  6.5
44–72
61  8.3
50–90
Leaf (R1) 85  13
66–110
83  13
60–110
Stalk (R1) 51  4.6
44–60
53  8.5
44–82
Root (R1) 33  19
5.7–57
31  15
7.8–54
Grain(R6) 30  9.0
14–54
31  9.9
17–60
Cry35Ab1
Pollen (R1) <LOQ <LOQ
Leaf (R1) 76  11
57–96
71  13
49–100
Stalk (R1) 16  1.9
13–20
23  5.8
15–34
Root (R1) 10  5.2
2.4–23
11  3.4
3.0–18
Grain(R6) 1.3  0.35
0.69–2.2
1.3  3.2
0.84–2.0
PAT
Pollen (R1) <LOQ <LOQ <LOQ
Leaf (R1) 30  5.1
20–43
8.5  1.7
5.1–13
18  3.9
9.0–30
Stalk (R1) 0.31  0.078
0.22–0.56
0.35  0.35
<LOQ–1.1
0.95  0.87
0.16–2.6
Root (R1) 1.2  0.87
<LOQ–2.4
0.28  0.17
<LOQ–0.60
0.79  0.53
<LOQ–1.5
Grain(R6) 0.075  0.019
<LOQ–0.15
<LOQ 0.072  0.015
<LOQ–0.15
Cry1Ab1
Pollen (R1) <LOQ <LOQ
Leaf (R1) 24  4.4
17–33
24  8.2
13–38
48 Part I – Section D.3 and Annex 4e.
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1507 3 59122 3
MON810 3 NK603
1507 59122 MON810 NK603
Stalk (R1) 5.9  0.57
4.8–7.2
6.6  0.98
4.8–7.8
Root (R1) 5.2  2.5
1.4–9.9
5.3  1.7
1.4–7.5
Grain(R6) 0.24  0.094
0.096–0.54
0.26  0.074
0.084–0.39
CP4 EPSPS1
Pollen (R1) 260  20
230–290
260  19
230–290
Leaf (R1) 180  15
150–200
170  38
110–240
Stalk (R1) 62  4.5
52–74
63  8.0
48–86
Root (R1) 43  15
15–66
42  16
6.9–63
Grain(R6) 8.9  3.0
3.9–17
12  3.0
7.2–20
1The 1507 9 59122 9 MON810 9 NK603 samples analysed for Cry1Ab and CP4 EPSPS come from plants treated with the
intended herbicide.
(a): Mean.
(b): Standard deviation.
(c): Range.
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